Dipeptidyl Peptidase-4 Inhibitors Show Better Glycemic Durability Compared to Sulfonylureas

November 2, 2017. Eight randomized controlled trials were included in this meta-analysis that demonstrated the superior durability of glycemic response for dipeptidyl peptidase-4 (DPP-4) inhibitors vs sulfonylureas (SUs) in patients with type 2 diabetes. Changes in A1C levels were compared from an intermediate timepoint of 26 or 52 weeks’ treatment to 104 weeks. DPP-4 inhibitors were associated with significantly smaller increases in A1C levels vs SUs from 24-28 weeks (mean difference [MD]: −0.16%, 95% confidence interval [CI]: −0.21, −0.11; P<0.001) and 52 weeks (MD: −0.06%, 95% CI: −0.10, −0.02; P=0.001) to 104 weeks. These results demonstrate that DPP-4 inhibitors are associated with improved duration of glycemic response than SUs and may be more effective than SUs at preserving islet beta-cell function. Read the abstract here.